Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure

Journal of Cardiac Failure

Volumn 10, Issue 1, 2004, Pages 83-89

  Xu, Jiang ^a,b   Carretero, Oscar A ^a   Liu, Yun He ^a   Yang, Fang ^a,c   Shesely, Edward G ^a   Oja Tebbe, Nancy ^a   Yang, Xiao Ping ^a  

^a HENRY FORD HOSPITAL   (United States)

^b WUHAN UNIVERSITY   (China)

^c North Coal Medical College   (China)

Author keywords

atrial natriuretic factor; Bradykinin; omapatrilat; ramipril

Indexed keywords

CANDOXATRIL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; OMAPATRILAT; RAMIPRIL; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE REMODELING; HEART WEIGHT; HISTOPATHOLOGY; INTERSTITIUM; KNOCKOUT MOUSE; LIVER WEIGHT; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; COLLAGEN; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HEART; HEART FAILURE, CONGESTIVE; INDANS; LIVER; LUNG; MICE; MICE, KNOCKOUT; MUSCLE CELLS; NEPRILYSIN; ORGAN SIZE; PROPIONATES; PYRIDINES; RAMIPRIL; THIAZEPINES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 3042736194     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardfail.2003.08.008     Document Type: Article

References (39)

1. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153
2. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 342:1993;821-828
3. Blais C.J., Fortin D., Rouleau J.-L., Molinaro G., Adam A. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. J Pharmacol Exp Ther. 295:2000;621-626
4. 2 kinin receptor gene knockout mice. Circ Res. 88:2001;1072-1079
5. Liu Y.-H., Yang X.-P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists in rats with heart failure. J Clin Invest. 99:1997;1926-1935
6. Cohn J.N. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. [editorial] Circulation. 91:1995;2504-2507
7. Liu Y.-H., Yang X.-P., Mehta D., Bulagannawar M., Scicli G.M., Carretero O.A. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol. 278:2000;H507-H514
8. Liu Y.-H., Xu J., Yang X.-P., Yang F., Shesely E., Carretero O.A. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension. 39:2001;375-381
9. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. for the Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53
10. Chen H.H., Grantham J.A., Schirger J.A., Jougasaki M., Redfield M.M., Burnett J.C. Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol. 36:2000;1706-1712
11. Maki T., Nasa Y., Yamaguchi F., Yoshida H., Mori M., Takada T., et al. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res. 51:2001;608-617
12. Northridge D.B., Currie P.F., Newby D.E., McMurray J.J., Ford M., Boon N.A., et al. Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Eur J Heart Fail. 1:1999;67-72
13. Ando S., Rahman M.A., Butler G.C., Senn B.L., Floras J.S. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 26:1995;1160-1166
14. Trippodo N.C., Fox M., Monticello T.M., Panchal B.C., Asaad M.M. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 34:1999;782-790
15. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. for the IMPRESS investigators. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20.
16. Dumoulin M.-J., Adam A., Rouleau J.-L., Lamontagne D. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol. 37:2001;359-366
17. 2 receptor knockout mice. Biochem Biophys Res Commun. 224:1996;625-630
18. Yang X.-P., Liu Y.-H., Shesely E.G., Bulagannawar M., Liu F., Carretero O.A. Endothelial nitric oxide gene knockout mice. Cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension. 34:1999;24-30
19. Yang X.-P., Liu Y.-H., Rhaleb N.-E., Kurihara N., Kim H.E., Carretero O.A. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol. 277:1999;H1967-H1974
20. 1 antagonists in mice. Hypertension. 40:2002;244-250
21. Skinner S.L., Dunn J.R., Mazzetti J., Campbell D.J., Fidge N.H. Purification, properties and kinetics of sheep and human renin substrates. Aust J Exp Biol Med Sci. 53:1975;77-88
22. Westfall P.H., Tobias R.D., Rom D., Wolfinger R.D., Hochberg Y. Multiple Comparisons and Multiple Tests Using the SAS System. 1999;SAS Institute, Cary, NC
23. Ball S.G., Hall A.S., Murray G.D. ACE inhibition, atherosclerosis and myocardial infarction - the AIRE Study in practice. Eur Heart J. 15:(Suppl B):1994;20-25
24. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., et al., on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752
25. Raut R., Rouleau J.-L., Blais C. Jr., Gosselin H., Molinaro G., Sirois M.G., et al. Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol. 276:1999;H1769-H1779
26. Wilkins M.R., Redondo J., Brown L.A. The natriuretic-peptide family. Lancet. 349:1997;1307-1310
27. Westheim A.S., Bostrom P., Christensen C.C., Parikka H., Rykke E.O., Toivonen L. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. J Am Coll Cardiol. 34:1999;1794-1801
28. Elsner D., Müntze A., Kromer E.P., Riegger G.A. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. Am J Cardiol. 70:1992;494-498
29. Kokkonen J.O., Kuoppala A., Saarinen J., Lindstedt K.A., Kovanen P.T. Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase. Circulation. 99:1999;1984-1990
30. Yang X.-P., Liu Y.-H., Peterson E., Carretero O.A. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: the role of kinins. J Cardiovasc Pharmacol. 29:1997;250-256
31. Richards A.M., Wittert G.A., Crozier I.G., Espiner E.A., Yandle T.G., Ikram H., et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 11:1993;407-416
32. Fuller F., Porter J.G., Arfsten A.E., Miller J., Schilling J.W., Scarborough R.M., et al. Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones. J Biol Chem. 263:1988;9395-9401
33. Robl J.A., Sun C.Q., Stevenson J., Ryono D.E., Simpkins L.M., Cimarusti M.P., et al., Dual metalloprotease inhibitors. Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem. 40:1997;1570-1577
34. Campese V.M., Lasseter K.C., Ferrario C.M., Smith W.B., Ruddy M.C., Grim C.E., et al. Omapatrilat versus lisinopril. Efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension. 38:2001;1342-1348
35. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, et al. for the OVERTURE Study Group. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106:920-926.
36. Carretero O.A., Rhaleb N.-E. Kinins. Izzo J.L. Jr., Black H.R. Hypertension primer. 2002;39-41 American Heart Association/Council for High Blood Pressure Research, Dallas, TX
37. Vesterqvist O., Reeves R.A. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and angiotensin-converting enzyme activity in humans. Curr Hypertens Rep. 3:(Suppl 2):2001;S22-S27
38. Rhaleb N.-E., Peng H., Yang X.-P., Liu Y.-H., Mehta D., Ezan E., et al. Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension. Circulation. 103:2001;3136-3141
39. 1 bradykinin receptor in normotension and hypertension. Circ Res. 88:2001;275-281